Masimo Receives CE Mark for AI-Powered smartSedLine™ Brain Function Monitor to Advance Anesthetic Management
Masimo has received CE Mark for its new AI-powered smartSedLine™ brain function monitor, which features an enhanced Patient State Index (PSi) algorithm. This technology is designed to provide more responsive and stable insights into brain activity during anesthesia, particularly during induction and in challenging low-power EEG conditions. The smartSedLine aims to help clinicians optimize anesthetic management and individualize patient care.
Masimo Shareholder Action Reminder
Faruqi & Faruqi, LLP is investigating potential claims against Masimo Corporation (NASDAQ: MASI) and reminds investors of the October 23, 2023 deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Masimo misled investors by providing flawed revenue guidance for fiscal 2023, failing to adequately account for potential losses in sensor sales and a decline in demand for luxury audio products. This alleged misrepresentation led to a nearly 20% drop in Masimo's stock price on July 18, 2023, after the company announced lower than expected Q2 2023 earnings and decreased full-year revenue estimates.
Masimo Number of Employees 2026 | Employee Count & Headcount Data
Masimo Corp. has approximately 5,257 total employees worldwide as of March 2026, marking an 11.3% decline from 2023. The company, headquartered in Irvine, California, is actively hiring, with 199 job postings in 2026, despite a decrease in new postings per month. Its workforce is concentrated in North America, and the average salary is $81,627, though employee sentiment is generally negative but improving.
Masimo Corp (MASI): Pentwater Capital files 13G/A showing exit from common stock
Pentwater Capital Management LP and Matthew Halbower have filed an amended Schedule 13G/A, indicating they no longer beneficially own common stock in Masimo Corporation (MASI). The filing reports a 0% ownership stake, with 0 shares beneficially owned and no voting or dispositive power. This updated disclosure signifies their complete exit from their common stock position in Masimo.
Masimo Shareholder Alert
Faruqi & Faruqi, LLP is investigating potential claims against Masimo Corporation (NASDAQ: MASI) and reminds investors of the October 23, 2023 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that Masimo misled investors about its sales pipeline and provided flawed revenue guidance for fiscal 2023, leading to a nearly 20% stock price drop on July 18, 2023, after lower than expected Q2 2023 earnings were announced. Investors who suffered losses exceeding $100,000 between February 28, 2023, and July 17, 2023, are encouraged to contact the firm.
Masimo Shareholder Action Reminder
Faruqi & Faruqi, LLP is investigating potential claims against Masimo Corporation (NASDAQ: MASI) and reminds investors of the October 23, 2023 deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Masimo misled investors about its sales pipeline and revenue guidance for fiscal 2023, leading to a significant stock price decline on July 18, 2023, after lower-than-expected Q2 2023 earnings were announced. Investors who suffered losses exceeding $100,000 between February 28, 2023, and July 17, 2023, are encouraged to contact the firm.
Masimo Deadline Alert
Faruqi & Faruqi, LLP is investigating potential claims against Masimo Corporation (NASDAQ: MASI) and reminds investors of the October 23, 2023 deadline to seek lead plaintiff status in a federal securities class action. The lawsuit alleges that Masimo misled investors with materially flawed revenue guidance for fiscal 2023, failing to account for potential loss of sensor sales and declining demand in premium audio. This alleged misinformation led to a significant stock price drop following Masimo's Q2 2023 earnings announcement.
Masimo Appoints Tim Benner as President
Masimo, a Danaher company, has appointed Tim Benner as its new President, effective August 3, 2026. Benner previously served as Masimo's Chief Marketing and Strategy Officer and Chief Commercial Officer, playing a crucial role in the company's strategy and transition after Danaher's acquisition. With over 30 years of experience in medical technology, Benner will lead Masimo's global business, focusing on innovation, strengthening customer partnerships, and accelerating commercial growth.
Masimo Appoints New President
Masimo has appointed Tim Benner as its new president, effective August 3, 2026. Benner, who previously served as chief marketing and strategy officer and chief commercial officer, brings over 30 years of medical technology leadership experience. In his new role, he will oversee global business operations, drive innovation in patient monitoring, and strengthen customer partnerships for Masimo, which is now a Danaher company.
Masimo Shareholder Action Reminder
Faruqi & Faruqi, LLP is investigating potential claims against Masimo Corporation (NASDAQ: MASI) and reminds investors of the October 23, 2023 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that Masimo misled investors regarding its sales pipeline and revenue guidance for fiscal 2023, leading to a significant stock price drop on July 18, 2023, after the company announced lower than expected Q2 2023 earnings and decreased full-year revenue estimates. Investors who suffered losses exceeding $100,000 between February 28, 2023, and July 17, 2023, are encouraged to contact the firm.
Masimo Deadline Reminder
Faruqi & Faruqi, LLP is investigating potential claims against Masimo Corporation (NASDAQ: MASI) and reminds investors of the October 23, 2023 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that Masimo misled investors by providing flawed revenue guidance for fiscal 2023, failing to account for potential loss of sensor sales and declining demand in audio categories, leading to a significant stock price drop on July 18, 2023. Investors who purchased Masimo securities between February 28, 2023, and July 17, 2023, and suffered losses are encouraged to contact the firm.
Masimo Retains $634 Million Patent Win Over Apple Watch Feature
A federal judge in California upheld a jury's $634 million patent verdict in favor of Masimo Corp. against Apple Inc., concerning heart-rate monitoring features in Apple Watches. The judgment, issued by Judge James V. Selna, preserves Masimo's November 2025 trial win regarding the patent infringement. However, the judge largely sided with Apple on trade secret claims that were part of earlier trials.
Apple loses its bid to get out of paying Masimo $634 million
Apple has lost its attempt to overturn a jury's decision requiring it to pay Masimo Corp. $634 million for patent infringement. A California judge rejected Apple's challenge and its request for a new trial, marking a significant development in the ongoing legal dispute. Masimo had previously accused Apple of infringing on patents related to blood oxygen level measurement in the Apple Watch and of stealing trade secrets and attempting to hire away key employees.
Apple loses bid to overturn $634 million Masimo patent verdict, new trial also denied
A federal judge denied Apple's requests to overturn a $634 million patent verdict and secure a new trial in its ongoing legal dispute with Masimo. The verdict found that Apple Watch's heart-rate monitoring and notification features infringed on a Masimo pulse oximetry patent. The judge sided with the jury's conclusion that the Apple Watch can be considered a "patient-monitoring device" under the patent and rejected Apple's arguments for a new trial.
Denon AVR-X1800H by Masimo Corp. - compact 8K receiver for Dolby Atmos living rooms
Masimo Corp. has released the Denon AVR-X1800H, a compact 7.2-channel AV receiver designed for Dolby Atmos living rooms and smaller home cinemas. This 8K-ready receiver features HDMI 2.1 inputs, HEOS multiroom streaming, and Audyssey MultEQ room correction, targeting consumers who desire modern immersive audio and streaming capabilities without a flagship system price. The AVR-X1800H contributes to Masimo’s steady revenue in home entertainment hardware, complementing its other product lines.
Apple loses its bid to get out of paying Masimo $634 million
Apple has lost its appeal to avoid paying Masimo $634 million after a California judge rejected its challenge to a jury's finding of patent infringement. This decision is the latest development in a long-standing legal battle where Masimo accused Apple of infringing on patents related to blood oxygen measurement technology in the Apple Watch and stealing trade secrets. Despite Apple's efforts, the ruling confirms the initial judgment against the tech giant.
Masimo Retains $634 Million Patent Win Over Apple Watch Feature
A federal judge in California has upheld a jury's $634 million patent verdict in favor of Masimo Corp. against Apple Inc., concerning heart-rate monitoring features in Apple Watches. While the judgment preserved Masimo's November 2025 trial win regarding the patent, it largely sided with Apple on trade secret claims that were previously litigated.
Denon AVR-X2800H by Masimo Corp. - mid-range receiver gets HEOS and 8K update
The Denon AVR-X2800H, produced by Masimo Corp. (under its Sound United brand), is a mid-range 7.2-channel AV receiver featuring 8K HDMI and HEOS multi-room streaming. Positioned for home theater enthusiasts, it includes modern HDMI 2.1 features for gamers and supports immersive audio formats like Dolby Atmos and DTS:X. This product contributes to Masimo's consumer segment revenue, diversifying its financial drivers beyond medical technology.
Qiagen M&A Fever Builds: KKR, EQT, Advent Explore Possible Takeover
Several private equity firms, including EQT, Advent, and KKR, are reportedly considering a takeover bid for Qiagen NV. This speculation follows Qiagen's ongoing strategic review and renewed investor interest, with potential offers of at least $50 per share. The planned departure of CEO Thierry Bernard is seen as removing a key obstacle, making the company more attractive to buyers amidst continued consolidation in the life sciences sector.
Masimo Corp highlights patient monitoring portfolio as Nasdaq-listed medical technology player
Masimo Corp, a Nasdaq-listed medical technology company, is spotlighting its non-invasive patient monitoring solutions, particularly its advanced pulse oximetry and hospital connectivity platforms. The company's technology is designed to deliver accurate vital sign measurements even in challenging clinical environments and integrates real-time patient data into hospital information systems, supporting streamlined workflows and improved patient safety. Masimo's diversified portfolio of hardware, software, and connectivity solutions provides a robust offering for healthcare providers and a strong investment case in the healthcare technology sector.
Masimo Corp focuses on patient monitoring innovation as investors assess long-term growth prospects
Masimo Corp is a medical technology company specializing in noninvasive patient monitoring solutions. The company's business model focuses on providing monitoring platforms, sensors, and software, generating recurring revenue through hardware sales and consumables. Investors are considering Masimo's long-term growth prospects, competitive position, and ability to innovate within the evolving medical devices and healthcare technology sector.
Masimo Radius T from Masimo Corp. - wireless wearable for hospital telemetry
Masimo Radius T is a new wireless, wearable patient telemetry device designed for use in US hospitals. It allows continuous monitoring of vital signs like heart rate and respiration via Bluetooth and Wi-Fi, enabling patients to move freely without being tethered. This device aims to automate patient monitoring, reduce manual charting, and enhance flexibility in hospital wards, strengthening Masimo's position in the hospital automation market.
Masimo Corporation Actuals & Estimates (GETTEX:3M4)
This article provides an overview of Masimo Corporation's (GETTEX:3M4) financial actuals and estimates. It includes current stock price, ticker information, analyst forecasts, historical price data, volatility, market capitalization, and details on net income, EBITDA, and employee count. The article also touches upon investment advice and where to find more detailed financial reports and technical analysis.
Masimo Corporation Actuals & Estimates (BMV:MASI)
This article provides an overview of Masimo Corporation's (BMV:MASI) financial actuals and estimates, including its stock performance, analyst forecasts, and company fundamental data. It covers aspects like current stock price, market capitalization, earnings reports, and volatility, along with general investment disclaimers.
Enterprise value to EBITDA forward of Masimo Corporation – BMV:MASI
This article displays the "Enterprise value to EBITDA forward" for Masimo Corporation (BMV:MASI) on TradingView. It indicates that the company's market is currently closed with no trades. The article is primarily a display of financial data in chart format with a large amount of navigation and footer content.
Price to earnings forward of Masimo Corporation – BMV:MASI
This article provides financial information for Masimo Corporation (BMV:MASI), specifically focusing on its price to earnings forward. It indicates that the market is currently closed with no trades. The content is primarily a data placeholder within a financial platform, showing the company's stock ticker and market details.
Masimo Receives FDA 510(k) Clearance for AI-Enabled Opioid-Induced Respiratory Depression (OIRD) Detection on Radius VSM® to Help Identify Respiratory Risk Sooner
Masimo, a Danaher company, has received FDA 510(k) clearance for its new AI-enabled Opioid-Induced Respiratory Depression (OIRD) detection feature integrated into the Radius VSM® wearable continuous patient monitor. This advanced capability utilizes Masimo's smart SET™ pulse oximetry platform and pattern recognition to help clinicians identify early signs of respiratory compromise in patients on opioid therapy. The innovation aims to enhance patient safety by providing earlier insights and supporting more informed decisions in hospital settings.
Masimo wins FDA clearance for wearable opioid-risk monitor
Masimo, a Danaher company, has received FDA 510(k) clearance for its AI-enabled Opioid-Induced Respiratory Depression (OIRD) detection capability integrated into the Radius VSM® wearable continuous patient monitor. This new feature utilizes advanced pattern recognition with Masimo’s smart SET™ pulse oximetry sensor platform to help clinicians identify early signs of respiratory compromise in hospital patients on opioid therapy. The clearance aims to enhance patient safety by providing earlier insights and supporting faster clinical decisions.
[15-12G] MASIMO CORP SEC Filing
This SEC filing (Form 15-12G) indicates that Masimo Corporation (MASI) is terminating its registration under Section 12(g) of the Securities Exchange Act of 1934 and suspending its duty to file reports. This action follows Masimo's acquisition by Danaher Corporation, which was completed on June 10, 2026. As a result of the merger, Masimo is now a wholly owned subsidiary of Danaher.
Masimo Corp (MASI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Masimo Corp (MASI), detailing its regional revenue contributions. As of the latest update on April 6, the United States is the largest contributor, accounting for 62.65% of revenue, followed by Europe, Middle East and Africa. Data for business segments and future fiscal years (FY2024, FY2025) have not yet been disclosed by the company.
Masimo CEO stepping down following acquisition by Danaher
Masimo CEO Katie Szyman is stepping down from her role following the company's acquisition by Danaher. The article, published on June 15, 2026, details this leadership change after the recent acquisition.
Masimo (MASI) CEO awards canceled, paid $180 per share in Danaher deal
Masimo's CEO, Catherine M. Szyman, had all her equity awards and common stock canceled or converted as part of the company's merger with Danaher, which closed on June 10, 2026. Shareholders received $180.00 per share in cash for their common stock, while Szyman's unvested restricted stock units were converted into Danaher RSUs and outstanding options and performance-based RSUs were cashed out based on the merger price. This transaction resulted in Szyman holding no remaining Masimo equity.
Masimo (MASI) director’s shares and RSUs cashed out at $180 in Danaher merger
Masimo director Darlene J. S. Solomon reported the disposition of her Masimo common stock and Restricted Stock Units (RSUs) as part of the company's merger with Danaher Corporation. On June 10, 2026, all 3,015 shares and 1,119 RSUs were converted into a cash right of $180 per share. This transaction resulted in Solomon holding no Masimo common stock or RSUs post-merger.
Masimo (MASI) executive reports stock and RSU disposition in Danaher merger
An executive at Masimo (MASI), Paul Hataishi, reported the disposition of his common stock and Restricted Stock Units (RSUs) due to Masimo's merger with a Danaher subsidiary. All 13,317 of Hataishi's common shares were converted into $180.00 cash per share, and his unvested Masimo RSUs were assumed by Danaher and converted into Danaher RSUs based on specific merger terms. This transaction has resulted in Hataishi holding no direct Masimo common stock or RSUs post-merger.
Masimo (MASI) director’s shares and RSUs cashed out in Danaher merger
Masimo Corporation director Timothy J. Scannell reported the cash-out of his equity holdings, including 2,608 common shares and 1,119 restricted stock units (RSUs), as part of Masimo's merger with Danaher Corporation. Both common shares and RSUs were liquidated at $180.00 per share on June 10, 2026, leaving Scannell with no direct common stock holdings. This transaction was in accordance with the merger agreement, where Masimo became a wholly-owned subsidiary of Danaher.
Masimo (MASI) CFO exits company stock as Danaher cash merger closes
Masimo Corporation's CFO, Micah W. Young, disposed of all his Masimo equity interests on June 10, 2026, as the company merged into a wholly-owned subsidiary of Danaher Corporation. Each Masimo common share was converted into $180.00 cash, with outstanding performance-based restricted stock units also converted to cash at the same rate. Other restricted stock units were assumed by Danaher and converted into Danaher RSUs, reflecting a mechanical disposition due to the merger rather than an open-market trade.
Politan Capital and Quentin Koffey cash out Masimo (MASI) at $180 per share
Insiders associated with Politan Capital, including Quentin Koffey, have fully divested their holdings in Masimo (MASI) following its merger with Danaher. On June 10, 2026, over 4.5 million common shares and 1,119 restricted stock units were converted into cash at a price of $180.00 per share. This transaction signifies the completion of the merger and shifts the investment focus to Danaher.
[Form 4] MASIMO CORP Insider Trading Activity
A recent Form 4 filing reveals that Politan Capital Management's fund restructured its Masimo (MASI) exposure by terminating two forward sale contracts. These contracts, involving 142,681 and 130,869 MASI common shares, were initiated in March 2026 with upfront payments based on a $175.48/share trade price. Following a merger on June 10, 2026, the contracts were terminated, and Politan paid counterparties based on a $180.00/share price.
Masimo (MASI) director’s shares and RSUs cashed out in Danaher merger
Masimo Corporation's merger with Danaher Corporation closed on June 10, 2026, resulting in Masimo Director Michelle Brennan's equity being cashed out. She disposed of 9,309 common shares and had 1,119 restricted stock units canceled, all converted into a right to receive $180.00 per share. These transactions, directly with the issuer, mean Brennan holds no remaining Masimo shares or RSUs in this account.
Masimo (MASI) bought out for $180 per share as Politan exits stake
Masimo Corporation (MASI) completed its merger on June 10, 2026, with all common shareholders receiving $180.00 cash per share. Politan Capital Management, previously a major shareholder with 4,590,873 shares, and Quentin Koffey, with 1,119 restricted share units, have now fully exited their stakes, reporting 0 shares and 0.0% beneficial ownership. This SEC filing confirms the merger's closing and Masimo's transition to a wholly-owned subsidiary.
Masimo Corporation(NasdaqGS:MASI) dropped from S&P 400 Health Care
Masimo Corporation (NasdaqGS: MASI) has been dropped from the S&P 400 Health Care index, accompanied by several other S&P and NASDAQ composite index removals on June 9th and 10th. The medical technology company, known for its monitoring technologies and patient care solutions, has experienced these changes amidst broader revisions to various market indices. The article also provides a company profile and rating information.
MASIMO CORP SEC Filing
Masimo Corporation has filed a post-effective amendment to deregister all unsold securities previously registered on its Form S-3. This action follows the completion of its merger with Danaher Corporation on June 10, 2026, which resulted in Masimo becoming a wholly-owned subsidiary of Danaher. The filing terminates all offerings under the specified registration number, reflecting the administrative change after the corporate acquisition.
Masimo Received Notice of Delisting
Masimo (MASI) has received a notice of delisting from Nasdaq following its merger. Trading in its common stock ceased prior to market open on the closing date, and the company plans to file Form 15 to terminate its registration and suspend reporting obligations after Form 25 becomes effective.
[8-K] MASIMO CORP Reports Material Event
Danaher Corporation has completed its acquisition of Masimo Corporation for an all-cash consideration of $180.00 per share, making Masimo a wholly-owned subsidiary. As a result, Masimo's common stock ceased trading on Nasdaq, will be delisted and deregistered, and all prior stockholder rights have been terminated, other than the right to receive the cash merger consideration. The acquisition also led to the resignation of Masimo's pre-closing directors, and certain executives entered into separation and short-term consulting agreements while receiving change-in-control severance benefits.
Masimo Corporation stock hits 52-week high at 179.98 USD
Masimo Corporation stock has reached a 52-week high of $179.98, reflecting a 7.09% increase over the past year and significant surges in recent months. Despite trading slightly above its Fair Value according to InvestingPro, the company boasts strong financial health with a perfect Piotroski Score of 9. Recent analyst activity has focused on its acquisition by Danaher, leading to both a raised price target from Jefferies and a downgrade from Raymond James.
Discontinued operations of Masimo Corporation – XETR:3M4
This article briefly mentions the discontinued operations of Masimo Corporation, traded under the symbol XETR:3M4 on the Deutsche Borse Xetra. It appears to be a financial data page from TradingView, indicating a market status of "closed" with no trades. The main content focuses on financial information for the company.
Diluted shares outstanding of Masimo Corporation – XETR:3M4
This article provides financial data for Masimo Corporation (XETR:3M4), specifically focusing on its diluted shares outstanding. It notes that the market is closed with no trades and gives an overview of various financial data services and products offered by TradingView.
MASI Stock Price Prediction 2025-2026 | Masimo Corporation Forecast
24/7 Wall St. rates Masimo Corporation (MASI) as a "BUY" with a 12-month target price of $240.23, suggesting a 34.37% upside from its current price of $178.78. The analysis includes optimistic and conservative scenarios, projecting potential highs of $258.11 and lows of $202.16, respectively. The long-term forecast for 2030 anticipates an average price of $348.95, representing a potential 95.2% return.
Masimo Deadline Alert
Faruqi & Faruqi, LLP is investigating potential claims against Masimo Corporation (NASDAQ: MASI) and reminds investors of the October 23, 2023 deadline to seek lead plaintiff status in a federal securities class action. The lawsuit alleges that Masimo misled investors about its sales pipeline and revenue guidance, causing a significant stock price drop on July 18, 2023, after lower-than-expected Q2 2023 earnings were announced. Investors who suffered losses exceeding $100,000 between February 28, 2023, and July 17, 2023, are encouraged to contact the law firm.
Masimo Shareholder Action Reminder
Faruqi & Faruqi, LLP is investigating potential claims against Masimo Corporation (NASDAQ: MASI) and reminds investors of the October 23, 2023 deadline to seek the role of lead plaintiff in a federal securities class action. The lawsuit alleges that Masimo misled investors regarding its sales pipeline and revenue guidance, leading to a significant stock price drop after lower-than-expected Q2 2023 earnings were announced on July 17, 2023. Investors who suffered losses exceeding $100,000 between February 28, 2023, and July 17, 2023, are encouraged to contact the firm.
